More on ONC
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $382.27 |
|
|||
| Open | $384.40 | ||||
| 52 Wk High | $0.35 | ||||
| 52 Wk Low | $0.35 | ||||
| Day High | $384.40 | ||||
| Day Low | $372.65 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 315,805 | ||||
- BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
- BeOne cancer drug combo shows 27-month median OS in gastric trial
- BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
- BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
- BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
- BeOne Medicines (ONC) PT Raised to $425 at Morgan Stanley
- Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings
- Form 4 BeOne Medicines Ltd. For: Oct 13 Filed by: Wang Xiaodong
- BeOne Medicines (ONC) PT Raised to $459 at RBC Capital
- BeOne Medicines (ONC) PT Raised to $420 at Truist Securities
Entities mentioned with ONC
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Canaccord Genuity | View Related Stories »
- RBC Capital | View Related Stories »
- Show More...
